Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA

Hematopoietic Stem Cell Transplant For Patients With Dyskeratosis Congenita and Severe Aplastic Anemia

Transplantation with stem cells is a standard therapy in many centers around the world. Previous experience with stem cell transplantation therapy for leukemias, lymphomas, other cancers, aplastic anemia and other non-malignant diseases, has led to prolonged disease-free survival or cure for some patients. However, the high doses of pre-transplant radiation and chemotherapy drugs used, and the type of drugs used, often cause many side effects that are intolerable for some patients. Slow recovery of blood counts is a frequent complication of high dose pre-transplant regimens, resulting in a longer period of risk for bleeding and infection plus a longer time in the hospital.

Recent studies have shown that using lower doses of radiation and chemotherapy (ones that do not completely kill all of the patient's bone marrow cells) before blood or bone marrow transplant, may be a better treatment for high risk patients, such as those with Dyskeratosis Congenita (DC) or Severe Aplastic Anemia(SAA). These low dose transplants may result in shorter periods of low blood counts, and blood counts that do not go as low as with traditional pre-transplant radiation and chemotherapy. Furthermore, in patients with Dyskeratosis Congenita or SAA, the stem cell transplant will replace the blood forming cells with healthy cells.

It has recently been shown that healthy marrow can take and grow after transplantation which uses doses of chemotherapy and radiation that are much lower than that given to patients with leukemia. While high doses of chemotherapy and radiation may be necessary to get rid of leukemia, this may not be important to patients with Dyskeratosis Congenita or SAA. The purpose of this research is to see if this lower dose chemotherapy and radiation regimen followed by transplant is a safe and effective treatment for patients with Dyskeratosis Congenita or SAA.

Study Overview

• Status: Completed
• Conditions: Aplastic Anemia; Dyskeratosis Congenita
• Intervention / Treatment: Drug: Campath 1H; Drug: Cyclophosphamide; Drug: Fludarabine; Procedure: Total Body Irradiation; Procedure: Stem Cell Transplantation; Drug: antithymocyte globulin; Drug: Methylprednisolone

Detailed Description

This is an open label, single arm, phase II clinical trial designed to evaluate the safety and efficacy of the treatment regimen. Efficacy will be measured by long-term engraftment of the transplanted cells.The primary endpoint of neutrophil engraftment is defined as an absolute neutrophil count (ANC) >5 x 108/L (first of three consecutive laboratory measurements on different days) with at least 10% donor cells by day 100. We will evaluate the proportion of success (P) and its 95% confidence interval (CI) for the entire group. The null hypothesis of 90% engraftment will be rejected if 4 or more patients fail to engraft out of 15 evaluable patients. The secondary endpoints of regimen related mortality, acute and chronic graft-versus-host disease (GVHD) and secondary malignancies will be estimated by cumulative incidence treating non-event deaths as a competing risk. Survival will be estimated by Kaplan-Meier methods. Immune reconstitution will be summarized with descriptive statistics.

SAA and DC arms will be analyzed separately.

• Study Type: Interventional
• Enrollment (Actual): 36
• Phase: Phase 2; Phase 3

Contacts and Locations

Study Locations

• United States
  • Minnesota
    • Minneapolis, Minnesota, United States, 55455
      • Masonic Cancer Center, University of Minnesota

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 68 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients with dyskeratosis congenita (DC) or severe aplastic anemia (SAA) 0-70 years of age with an acceptable hematopoietic stem cell (HSC) donor

  • HSC source

    • Human leukocyte antigen (HLA) identical or 1 antigen mismatched sibling or other relative eligible to donate bone marrow (BM), umbilical cord blood (UCB) or mobilized peripheral blood (PB) at cell doses that meet current institutional standards.
    • HLA identical or up to a 1 antigen mismatched unrelated donor.
    • Two units of unrelated umbilical cord blood (UCB) that are (a) up to 2 HLA antigens mismatched to the patient (b) up to 2 HLA antigens mismatched to each other, (c) minimum cell dose of ≥ 3.5 x 10^7 nucleated cells/kg and optimal cell dose ≥ 5 x 10^7 nucleated cells/kg.
    • If two units are not available: single unrelated UCB unit selected according to Minnesota Bone Marrow Transplant (BMT) program guidelines

  • Disease Characteristics for DC (both of the following):

    • Evidence of BM failure:

      • Requirement for red blood cell and/or platelet transfusions,
      • Requirement for granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) or erythropoietin, or
      • Refractory cytopenias defined as two out of three: platelets <40,000/microliter (uL) or transfusion dependent, Absolute neutrophil count <500/uL without hematopoietic growth factor support, Hemoglobin <9g/uL or transfusion dependent

    • Diagnosis of DC:

      • A triad of mucocutaneous features: oral leukoplakia, nail dystrophy, abnormal reticular skin hyperpigmentation.
      • Or one of the following: Short telomeres (under a research study), Dyskerin mutation, Telomerase RNA (TERC) mutation

  • Disease Characteristics for SAA (both of the following):

    • Evidence of BM failure:

      • Refractory cytopenia defined by bone marrow cellularity <25-50% (with < 30% residual hematopoietic cells)

    • Diagnosis of SAA:

      • Refractory cytopenias defined as two out of three: Platelets <20,000/uL or transfusion dependent, Absolute neutrophil count <500/uL without hematopoietic growth factor support, Absolute reticulocyte count <20,000/uL
  • Patients with early myelodysplastic features.
  • Patients with or without clonal cytogenetic abnormalities.

Patient Exclusion Criteria:

• Patients with one or more of the following:

  • Decompensated congestive heart failure; left ventricular ejection fraction <35%
  • Acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis on biopsy
  • Carbon Monoxide Diffusing Capacity (DLCO) <30% predicted, and oxygen requirement
  • Glomerular filtration rate (GFR) <30% predicted
  • Pregnant or lactating female
  • Active serious infection whereby patient has been on intravenous antibiotics for at least one week prior to study entry. Any patient with AIDS or HIV seropositivity. If recent mold infection e.g. Aspergillus - must have >30 days of appropriate treatment before HSC transplantation and infection must be controlled and cleared by the Infectious Disease consultant.
  • Cannot receive total body irradiation (TBI) due to prior radiation therapy
  • Diagnosis of Fanconi anemia based on diepoxybutane (DEB).
  • DC patients with advanced myelodysplastic syndrome (MDS) or acute myeloid leukemia with >30 blasts.
  • History of non hematopoietic malignancy within 2 years except resected basal cell carcinoma or treated carcinoma in situ.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Patients with DC; Patients with dyskeratosis congenita (DC). Patients are treated with alemtuzumab (Campath 1H), Cyclophosphamide, Fludarabine, total body irradiation and stem cell transplantation.	Drug: Campath 1H; 10, 9, 8, 7, and 6 days before transplant subjects will be given 1 dose of campath 1H given via catheter (0.2 mg/kg over 2 hours).; Other Names: Alemtuzumab; Drug: Cyclophosphamide; 7 days before the transplant, 1 dose of cyclophosphamide is given via catheter (50mg/kg IV over 2 hours).; Other Names: Cytoxan; Drug: Fludarabine; 6, 5, 4, 3, and 2 days before the transplant, 1 dose fludarabine is given via catheter (40 mg/kg IV over 1 hour); Other Names: Fludara; Procedure: Total Body Irradiation; 1 day before the transplant one dose (200 cGy) of total body irradiation is given; Other Names: Radiation therapy, therapeutic radiation; Procedure: Stem Cell Transplantation; Infusion of stem cells on Day 0.; Other Names: Bone Marrow Transplant
Experimental: Patients with SAA; Patients with severe aplastic anemia (SAA). Patients are treated with alemtuzumab (Campath 1H), Cyclophosphamide, Fludarabine, antithymocyte globulin, total body irradiation and stem cell transplantation.	Drug: Cyclophosphamide; 7 days before the transplant, 1 dose of cyclophosphamide is given via catheter (50mg/kg IV over 2 hours).; Other Names: Cytoxan; Drug: Fludarabine; 6, 5, 4, 3, and 2 days before the transplant, 1 dose fludarabine is given via catheter (40 mg/kg IV over 1 hour); Other Names: Fludara; Procedure: Total Body Irradiation; 1 day before the transplant one dose (200 cGy) of total body irradiation is given; Other Names: Radiation therapy, therapeutic radiation; Procedure: Stem Cell Transplantation; Infusion of stem cells on Day 0.; Other Names: Bone Marrow Transplant; Drug: antithymocyte globulin; ATG (rabbit) 3 mg/kg for 3 days.; Other Names: ATG; Thymoglobulin; Atgam; Drug: Methylprednisolone; 2mg/kg IV is given before each dose of antithymocyte globulin (ATG).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Neutrophil Engraftment	Defined as an absolute neutrophil count (ANC) >5 x 10^8/L (first of three consecutive laboratory measurements on different days) with at least 10% donor cells by day 100. Demonstrate sustained engraftment after a fludarabine based preparative regimen in patients with dyskeratosis congenita followed by hematopoietic cell transplantation.	Day 100

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Regimen Related Mortality at 100 Days	all deaths without previous relapse or progression	100 days
Incidence of Chronic GVHD	Chronic Graft-Versus-Host Disease is a severe long-term complication created by infusion of donor cells into a foreign host.	6 months
Incidence of Chronic GVHD	Chronic Graft-Versus-Host Disease is a severe long-term complication created by infusion of donor cells into a foreign host.	1 year
Incidence of Late Secondary Malignancies	Defined as patients who have a secondary malignancy (cancer) occurring.	1 Year
Incidence of Grade 2-4 Acute Graft Versus Host Disease (GVHD)	Acute Graft-Versus-Host Disease is a severe short-term complication created by infusion of donor cells into a foreign host.	Day 100
Incidence of Grade 3-4 Acute Graft Versus Host Disease (GVHD)	Acute Graft-Versus-Host Disease is a severe short-term complication created by infusion of donor cells into a foreign host.	Day 100
Overall Survival	Overall survival is defined as time from date of transplant to date of death or censored at the date of last documented contact for patients still alive.	Day 100
Overall Survival	Overall survival is defined as time from date of transplant to date of death or censored at the date of last documented contact for patients still alive.	1 Year
Incidence of Pulmonary Complications	Defined as patients who exhibit a pulmonary (lung) adverse event.	6 Months

Collaborators and Investigators

• Sponsor: Masonic Cancer Center, University of Minnesota
• Investigators: Principal Investigator: Jakub Tolar, M.D., Ph.D., Masonic Cancer Center, University of Minnesota

Publications and helpful links

General Publications

• Dietz AC, Orchard PJ, Baker KS, Giller RH, Savage SA, Alter BP, Tolar J. Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita. Bone Marrow Transplant. 2011 Jan;46(1):98-104. doi: 10.1038/bmt.2010.65. Epub 2010 Apr 12.

Study record dates

Study Major Dates

• Study Start: August 1, 2007
• Primary Completion (Actual): March 1, 2015
• Study Completion (Actual): June 1, 2016

Study Registration Dates

• First Submitted: March 30, 2007
• First Submitted That Met QC Criteria: March 30, 2007
• First Posted (Estimate): April 3, 2007

Study Record Updates

• Last Update Posted (Actual): December 5, 2017
• Last Update Submitted That Met QC Criteria: December 3, 2017
• Last Verified: December 1, 2017

More Information

Terms related to this study

• Keywords: Hematopoietic Stem Cell Transplantation; Severe Aplastic Anemia; Dyskeratosis Congenita
• Additional Relevant MeSH Terms: Skin Diseases; Congenital Abnormalities; Bone Marrow Diseases; Hematologic Diseases; Genetic Diseases, Inborn; Genetic Diseases, X-Linked; Skin Diseases, Genetic; Skin Abnormalities; Congenital Bone Marrow Failure Syndromes; Bone Marrow Failure Disorders; Anemia; Anemia, Aplastic; Dyskeratosis Congenita; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Anti-Inflammatory Agents; Antirheumatic Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Antiemetics; Gastrointestinal Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Neuroprotective Agents; Protective Agents; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Antineoplastic Agents, Immunological; Methylprednisolone; Cyclophosphamide; Fludarabine; Thymoglobulin; Antilymphocyte Serum; Alemtuzumab
• Other Study ID Numbers: MT2006-06; 0612M98727 (Other Identifier: Institutional Review Board, University of Minnesota)